Efficacy and Safety of Eculizumab in Asian Patients WithAquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder: Subgroup Analysis From the Phase 3 PREVENT Study

被引：0
|
作者：
Kim, H. J. [1 ]
Berthele, A. [2 ]
Fujihara, K. [3 ,4 ,5 ]
Levy, M. [6 ,7 ,8 ]
Palace, J. [9 ]
Nakashima, I. [3 ,10 ]
Totolyan, N. [11 ]
Viswanathan, S. [12 ]
Wang, K-C. [13 ,14 ]
Pace, A. [15 ]
Armstrong, R. [15 ]
Miller, L. [15 ]
Yountz, M. [15 ]
Wingerchuk, D. M. [16 ]
Pittock, S. J. [17 ]
机构：
[1] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[2] Tech Univ Munich, Klinikum Rechts Isar, Munich, Germany
[3] Tohoku Univ, Sendai, Miyagi, Japan
[4] Fukushima Med Univ, Fukushima, Japan
[5] Southern TOHOKU Res Inst Neurosci STRINS, Koriyama, Fukushima, Japan
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Harvard Med Sch, Boston, MA 02115 USA
[9] John Radcliffe Hosp, Oxford, England
[10] Tohoku Med & Pharmaceut Univ, Sendai, Miyagi, Japan
[11] First Pavlov State Med Univ St Petersburg, St Petersburg, Russia
[12] Kuala Lumpur Hosp, Kuala Lumpur, Malaysia
[13] Cheng Hsin Gen Hosp, Taipei, Taiwan
[14] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
[15] Alex Pharmaceut, Boston, MA USA
[16] Mayo Clin, Scottsdale, AZ USA
[17] Mayo Clin, Rochester, MN USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O-4
引用
收藏
页码：NP38 / NP39
页数：2
相关论文
共 50 条
  • [1] Long-term Safety and Efficacy of Eculizumab in Asian Patients With Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
    Fujihara, K.
    Berthele, A.
    Kim, H. J.
    Levy, M.
    Palace, J.
    Nakashima, I.
    Totolyan, N.
    Viswanathan, S.
    Wang, K-C.
    Pace, A.
    Armstrong, R.
    Carrillo-Infante, C.
    Miller, L.
    Wingerchuk, D. M.
    Pittock, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP84 - NP85
  • [2] Long-term efficacy and safety of eculizumab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder
    Wingerchuk, Dean
    Berthele, Achim
    Fujihara, Kazuo
    Oreja-Guevara, Celia
    Kim, Ho Jin
    Levy, Michael
    Nakashima, Ichiro
    Palace, Jacqueline
    Shang, Shulian
    Yountz, Marcus
    Miller, Larissa
    Pittock, Sean
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [3] Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study
    Oreja-Guevara, C.
    Palace, J.
    Pittock, S. J.
    Berthele, A.
    Fujihara, K.
    Levy, M.
    Nakashima, I.
    Pace, A.
    Miller, L.
    Sabatella, G.
    Wingerchuk, D. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 90 - 90
  • [4] Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study
    Levy, Michael
    Berthele, Achim
    Kim, Ho Jin
    Fujihara, Kazuo
    Nakashima, Ichiro
    Oreja-Guevara, Celia
    Palace, Jacqueline
    Pittock, Sean
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Pace, Amy
    Yountz, Marcus
    Lawson, Diane
    Meyer, Eva-Laudon
    Wingerchuk, Dean
    NEUROLOGY, 2020, 94 (15)
  • [5] Evidence of Muller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder
    You, Yuyi
    Zhu, Ling
    Zhang, Ting
    Shen, Ting
    Fontes, Ariadna
    Yiannikas, Con
    Parratt, John
    Barton, Joshua
    Schulz, Angela
    Gupta, Vivek
    Barnett, Michael H.
    Fraser, Clare L.
    Gillies, Mark
    Graham, Stuart L.
    Klistorner, Alexander
    OPHTHALMOLOGY, 2019, 126 (06) : 2019 - 810
  • [6] Efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder previously treated with rituximab: findings from PREVENT
    Levy, M.
    Berthele, A.
    Kim, H. J.
    Fujihara, K.
    Nakashima, I.
    Oreja-Guevara, C.
    Palace, J.
    Pittock, S.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Yountz, M.
    Lawson, D.
    Laudon-Meyer, E.
    Wingerchuk, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 1 - 2
  • [7] Subgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
    Pittock, S.
    Berthele, A.
    Fujihara, K.
    Kim, H. J.
    Levy, M.
    Palace, J.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Fujita, K. P.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D. M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 289 - 290
  • [8] Long-Term Visual Prognosis in Patients With Aquaporin-4-Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder
    Moon, Yeji
    Jang, Yeonji
    Lee, Haeng-Jin
    Kim, Sung-Min
    Kim, Seong-Joon
    Jung, Jae Ho
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2022, 42 (03) : 303 - 309
  • [9] Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension
    Kim, Ho Jin
    Nakashima, Ichiro
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Shang, Shulian
    Miller, Larisa
    Yountz, Marcus
    Wingerchuk, Dean M.
    Pittock, Sean J.
    Levy, Michael
    Berthele, Achim
    Totolyan, Natalia
    Palace, Jacqueline
    Barnett, Michael H.
    Fujihara, Kazuo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 50
  • [10] Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study
    Palace, J.
    Pittock, S. J.
    Berthele, A.
    Fujihara, K.
    Kim, H. J.
    Levy, M.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D. M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 737 - 738
12345